Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.
David J. Kuter(Harvard University), Dietmar Berger(Amgen (United States)), Francesco Rodeghiero(Ospedale San Bortolo), Dominik Selleslag(National Institutes of Health), Mathias Rummel(Universitätsklinikum Gießen und Marburg), Ingrid Pabinger(Medical University of Vienna), Beng H. Chong(The University of Texas Southwestern Medical Center), Xuena Wang(Tianjin University of Traditional Chinese Medicine), B. Gail Macik(University of Virginia), Ralph V. Boccia(Center for Cancer and Blood Disorders), H. Müller-Beiβenhirtz, Lara Gehl(Amgen (United States))
Cited by 7
Related Papers
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
|Clinical Infectious Diseases|2002|2.3k